Handbook of therapeutic antibodies : technologies, emerging developments and approved therapeutics
著者
書誌事項
Handbook of therapeutic antibodies : technologies, emerging developments and approved therapeutics
Wiley-Blackwell, 2010
Soft-cover ed
- : pbk
大学図書館所蔵 件 / 全4件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Originally published: Weinheim : Wiley-VCH , 2007
Originally published as a 3 vol. set
Includes bibliographical references and index
内容説明・目次
内容説明
Antibodies are an essential part of the immune system in vertebrates. Their generation involves a random mutation and rearrangement process and they can be in principle directed against any biological compound. In the last years biotechnological processes have been developed allowing for the selection of any antibody with a specific target and the subsequent large scale production of this antibody. This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a paperback edition. It includes general chapters presenting established technologies and clinical applications, chapters on emerging technologies, new therapeutic concepts, and clinical studies and detailed and specific information about currently approved therapeutic antibodies, including clinical data. This is a must-have resource for academic researchers and decision makers in the industry, as well as healthcare professionals in the clinic.
目次
Section I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection strategies I: Monoclonal Antibodies Selection strategies II: Antibody Phage Display Selection strategies III: Transgenic Mice Bioinformatic Tools for Antibody Engineering Molecular Engineering I: Humanization Molecular Engineering II: Affinity Maturation Molecular Engineering III: Fc Engineering PART II: THE WAY INTO THE CLINIC Production and Downstream Processing Pharmaceutical Formulation and Clinical Application Immunogenicity of Antibody Therapeutics Regulatory Considerations Intellectual Property Issues Section II: Emerging Developments PART III: BEYOND IGG: MODIFIED ANTIBODIES Immunoscintigraphy and Radioimmunotherapy Bispecific Antibodies Immunotoxins / Targeted RNases PART IV: EMERGING CONCEPTS Automation of Selection and Engineering Emerging Technologies for Antibody Selection Emerging Alternative Production Systems Non-Antibody Scaffolds Emerging Therapeutic Concepts I: ADEPT Emerging Therapeutic Concepts II: Nanotechnology Emerging Therapeutic Concepts III:Cell-bound antibodies Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies PART V: ONGOING CLINICAL STUDIES: Antibodies in Phase I/II/III: Cancer Therapy Antibodies in Phase I/II/III: Targeting TNF Section III: APPROVED THERAPEUTICS Adalimumab (Humira) Alemtuzumab (Mabcampath) Bevacizumab (Avastin) Cetuximab (Erbitux) Efalizumab (Raptiva) Fanolesomab/Technetium99m (Neutrospec) Gemtuzumab Ozogamicin (Mylotarg) Infliximab (Remicade) Muromonab (Orthoclone) Natalizumab (Tysabri) Omalizumab (Xolair) Palivizumab (Synagis) Rituximab (Rituxan) Trastuzumab (Herceptin) Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab Yttrium-90 Ibritumomab Tiuxetan (Zevalin)
「Nielsen BookData」 より